Psychedelic Therapy for Body Dysmorphic Disorder

Body dysmorphic disorder (BDD) is described as a chronic, severe psychiatric condition marked by preoccupations with perceived bodily or facial defects and repetitive behaviours such as camouflaging, skin picking, and mirror checking. Johnson and colleagues note rising rates of body image disturbance and increasing prevalence of BDD in adolescents and young adults, alongside persistent problems with treatment non-response, relapse, and under‑recognition. Although cognitive–behavioural therapy tailored to BDD (CBT‑BDD) and pharmacotherapies (SSRIs, TCAs) are first‑line treatments, substantial proportions of patients do not remit, many discontinue therapy, and comorbidity and high medication doses contribute to poor adherence and outcomes. Against this clinical backdrop, the authors propose that psychedelic‑assisted psychotherapy merits formal investigation as a potential treatment for BDD. Drawing on a range of preliminary clinical findings, case reports, survey and qualitative data, and theoretical models about self‑representation and perceptual processing, Johnson argues that there is a sufficient circumstantial case to justify a Phase 2a safety and feasibility study of psilocybin‑assisted therapy in people with BDD. The paper therefore outlines the rationale and offers practical suggestions for how early clinical research in this area might be designed and conducted.

This paper is an opinion and synthesis rather than an original empirical study. Johnson and colleagues review heterogeneous sources of evidence — including historical psychedelic research, contemporary controlled and open‑label trials in other psychiatric conditions, case reports, survey and qualitative studies in related disorders (notably eating disorders), and theoretical literature on self‑model revision — to build a rationale for trialling psychedelic therapy in BDD. Based on that synthesis, the authors recommend a first‑step Phase 2a approach to establish safety and feasibility. They suggest an initial clinical study that could take the form of an open‑label cohort, with participants randomised to a psilocybin‑assisted therapy condition or to a supportive psychotherapy control arm (the text notes supportive therapy as the common comparator in psychedelic studies). Safety monitoring would focus on the occurrence and severity of adverse events, graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 4. Feasibility outcomes proposed include self‑reported intensity of the psilocybin experience, recruitment success, and attrition rates. Practical and ethical design elements the authors highlight include recruiting from dermatology and plastic surgery settings to reach under‑recognised BDD cases, implementing an "enhanced consent" process that explains the potential for rapid and durable changes to personality and worldview, and coordinating with prescribing clinicians to manage tapering of antidepressants or other psychotropic medications where required. Johnson recommends psilocybin specifically, citing its established clinical research base and safety profile, and discusses therapeutic integration strategies such as pairing psilocybin sessions with CBT‑BDD components (for example, mirror retraining) while advising caution about exposing participants to mirrors during peak drug effects. The authors do not report a specific statistical analysis plan or sample size in the extracted text.

The paper does not present original empirical results; instead, Johnson summarises existing, predominantly indirect evidence relevant to the proposal that psilocybin‑assisted therapy could be investigated for BDD. Key empirical points drawn together are: - BDD epidemiology and current treatment outcomes: global prevalence estimates are reported at about 1 to 3%, with high morbidity; as many as 53% of patients seen in cosmetic surgery settings meet diagnostic criteria for BDD. Meta‑analytic evidence cited indicates a fourfold increase in suicidality and a 2.6‑fold greater likelihood of suicide attempts in BDD compared with controls. Response rates to CBT‑BDD are modest, with only about 40 to 54% of participants classified as treatment responders in a cited meta‑analysis, and attrition in CBT trials can be high (reported up to 56% in some analyses). - Safety and tolerability of psychedelics in other populations: contemporary controlled and open‑label studies in healthy volunteers and clinical groups have generally found that moderate‑to‑high doses of classic serotonergic psychedelics (including psilocybin) can be administered to carefully screened participants in controlled settings without serious or lasting adverse effects. Regulatory milestones referenced include FDA breakthrough therapy designations for psilocybin in treatment‑resistant depression and major depressive disorder. The Usona Institute (2020) is cited for an absence of reported pharmaceutical psilocybin overdoses. - Disorder‑specific and mechanistic signals: a single‑case report of a person with BDD who experienced reduced preoccupation and distress following psilocybin ingestion is presented as directly relevant. Survey and qualitative studies of naturalistic psychedelic use in people with eating disorders reported reductions in depression and self‑reported improvements in body image in some participants. A small double‑blind randomised trial in nine individuals with moderate to severe obsessive‑compulsive disorder found that psilocybin significantly reduced symptoms; two participants reported symptom relief lasting around one week and one participant remained in remission at six months. A case of phantom limb pain is described where mirror therapy paired with psilocybin produced sustained benefit, which the authors link conceptually to mirror‑based perceptual retraining used in CBT‑BDD. The authors emphasise that all of these data are preliminary and largely indirect with respect to BDD itself; they present them as a circumstantial but convergent basis for moving to a Phase 2a safety and feasibility trial rather than as proof of efficacy.

Johnson interprets the assembled evidence as warranting cautious, stepwise clinical investigation of psilocybin‑assisted therapy in BDD. They argue that multiple lines of preliminary data — case reports, survey and qualitative findings in related disorders, small clinical trials in OCD and depression, and theoretical work on self‑model revision and perceptual processing — converge to make a prima facie case for a Phase 2a study focused on safety and feasibility. The authors situate their proposal within the limitations of current BDD care: first‑line therapies are not universally effective, many patients are under‑recognised or present to non‑mental‑health settings, and treatment barriers such as shame, stigma, and preferences for self‑management impede engagement. They suggest pragmatic responses to these issues, including targeted recruitment from plastic surgery and dermatology clinics and the use of an enhanced consent process that explicitly addresses the potential for profound changes in personality or worldview following psychedelic experiences. Acknowledged uncertainties and cautions are prominent. Johnson stresses that the existing evidence is indirect and preliminary, and that trials should prioritise safety monitoring (adverse events graded by CTCAE v4), coordinated medication management (tapering antidepressants where appropriate), and ethical safeguards. Methodological caveats include the need to consider timing when combining perceptual retraining (for example mirror exposure) with psychedelic sessions, since perceptual distortions during the drug's peak could exacerbate appearance‑related biases; the authors recommend introducing mirror work after peak effects or during integration sessions. They also call for progression from Phase 2a feasibility studies to double‑blind randomized controlled trials if early evidence supports tolerability and safety, and for combining psilocybin with evidence‑based BDD interventions such as CBT‑BDD to target compulsions, cognitive rigidity, and perceptual biases. Overall, the discussion frames psychedelic therapy as a promising but unproven avenue that requires careful, ethically informed clinical research rather than immediate clinical adoption.

Johnson concludes that BDD is a debilitating and often treatment‑resistant condition for which new therapeutic approaches are needed. Based on the limited but suggestive evidence and relevant theoretical models, the authors advocate conducting a Phase 2a study of psilocybin‑assisted therapy to assess safety and feasibility in people with BDD. Such early clinical work could, if favourable, provide the foundation for subsequent randomised controlled trials and for integrating psychedelic administration with established BDD interventions like CBT‑BDD.